Supernus Pharmaceuticals
Market Cap
US$1.4b
Last Updated
2019/08/22 00:29 UTC
Data Sources
Company Financials +
Executive Summary
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States.
Snowflake
Fundamentals
Good value with adequate balance sheet.
Similar Companies
Share Price & News
How has Supernus Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.6%
NasdaqGM:SUPN
2.3%
US Pharmaceuticals
2.9%
US Market
1 Year Return
-38.8%
NasdaqGM:SUPN
-5.8%
US Pharmaceuticals
0.2%
US Market
SUPN underperformed the Pharmaceuticals industry which returned -6.8% over the past year.
SUPN underperformed the Market in United States of America which returned -0.7% over the past year.
Share holder returns
| SUPN | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.6% | 2.3% | 2.9% |
| 30 Day | -14.5% | -1.0% | -2.3% |
| 90 Day | -18.4% | -3.6% | 3.1% |
| 1 Year | -38.8%-38.8% | -3.5%-5.8% | 2.4%0.2% |
| 3 Year | 28.5%28.5% | 11.3%3.7% | 41.7%32.4% |
| 5 Year | 211.4%211.4% | 23.3%10.3% | 55.1%37.9% |
Price Volatility Vs. Market
How volatile is Supernus Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 37% Discount?1 week ago | Simply Wall St
What You Must Know About Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Beta Value3 weeks ago | Simply Wall St
Does Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) P/E Ratio Signal A Buying Opportunity?Valuation
Is Supernus Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?
36%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Supernus Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
Supernus Pharmaceuticals's share price is below the future cash flow value, but not at a substantial discount (< 40%).
Price Based on Earnings
Supernus Pharmaceuticals is good value based on earnings compared to the US Pharmaceuticals industry average.
Supernus Pharmaceuticals is good value based on earnings compared to the United States of America market.
Price Based on Expected Growth
Supernus Pharmaceuticals is poor value based on expected growth next year.
Price Based on Value of Assets
Supernus Pharmaceuticals is good value based on assets compared to the US Pharmaceuticals industry average.
Next Steps
Future Growth
How is Supernus Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 7 analysts?
12.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Supernus Pharmaceuticals's revenue is expected to grow by 9% yearly, however this is not considered high growth (20% yearly).
Supernus Pharmaceuticals's earnings are expected to grow by 12% yearly, however this is not considered high growth (20% yearly).
Supernus Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Supernus Pharmaceuticals's earnings growth is positive but not above the United States of America market average.
Supernus Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Supernus Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Supernus Pharmaceuticals performed over the past 5 years?
50.4%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Supernus Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.
Supernus Pharmaceuticals's 1-year earnings growth is less than its 5-year average (21.1% vs 50.4%)
Supernus Pharmaceuticals's earnings growth has not exceeded the US Pharmaceuticals industry average in the past year (21.1% vs 24.3%).
Return on Equity
Supernus Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
Return on Assets
Supernus Pharmaceuticals used its assets less efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
Return on Capital Employed
Supernus Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is Supernus Pharmaceuticals's financial position?
Financial Position Analysis
Supernus Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Supernus Pharmaceuticals's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
Supernus Pharmaceuticals's level of debt (64.5%) compared to net worth is high (greater than 40%).
The level of debt compared to net worth has been reduced over the past 5 years (84.9% vs 64.5% today).
Debt is well covered by operating cash flow (46.6%, greater than 20% of total debt).
Interest payments on debt are well covered by earnings (EBIT is 45x coverage).
Balance Sheet
Low level of unsold assets.
Debt is covered by short term assets, assets are 1.2x debt.
Next Steps
Dividend
What is Supernus Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Supernus Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Supernus Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Supernus Pharmaceuticals has not reported any payouts.
Unable to verify if Supernus Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Supernus Pharmaceuticals has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Supernus Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
7.1yrs
Average management tenure
CEO
Jack Khattar (58yo)
14.6yrs
Tenure
US$7,215,836
Compensation
Mr. Jack A. Khattar founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has been its Chief Executive Officer, President, Secretary and Director since 2005. From 1999 to ...
CEO Compensation Analysis
Jack's remuneration is higher than average for companies of similar size in United States of America.
Jack's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.
Management Age and Tenure
7.1yrs
Average Tenure
64yo
Average Age
The average tenure for the Supernus Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Board Age and Tenure
6.5yrs
Average Tenure
66.5yo
Average Age
The tenure for the Supernus Pharmaceuticals board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Jack Khattar (58yo)
Founder
- Tenure: 14.6yrs
- Compensation: US$7.22m
Gregory Patrick (68yo)
Senior VP & CFO
- Tenure: 7.8yrs
- Compensation: US$1.24m
Padmanabh Bhatt (62yo)
Chief Scientific Officer & Senior VP of Intellectual Property
- Tenure: 7.4yrs
- Compensation: US$1.23m
Tami Martin (64yo)
Senior Vice President of Regulatory Affairs
- Tenure: 0.0yrs
Stefan K. Schwabe (67yo)
Chief Medical Officer and Executive VP of Research & Development
- Tenure: 7.1yrs
- Compensation: US$1.28m
Todd Horich
Vice President of Marketing
- Tenure: 4.6yrs
Taylor Raiford
Vice President of Sales
- Tenure: 4.6yrs
Bryan Roecklein
Vice President of Corporate Development
- Tenure: 4.1yrs
Board Members
Chuck Newhall (74yo)
Chairman of the Board
- Tenure: 3.0yrs
- Compensation: US$298.13k
John Siebert (79yo)
Director
- Tenure: 8.6yrs
- Compensation: US$277.13k
Jack Khattar (58yo)
Founder
- Tenure: 14.6yrs
- Compensation: US$7.22m
Georges Gemayel (59yo)
Director
- Tenure: 4.4yrs
- Compensation: US$267.13k
Carrolee Barlow (55yo)
Director
- Tenure: 1.2yrs
- Compensation: US$365.09k
Frederick Hudson (74yo)
Director
- Tenure: 9.6yrs
- Compensation: US$282.13k
Company Information
Supernus Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Supernus Pharmaceuticals, Inc.
- Ticker: SUPN
- Exchange: NasdaqGM
- Founded: 2005
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.439b
- Shares outstanding: 52.45m
- Website: https://www.supernus.com
Number of Employees
Location
- Supernus Pharmaceuticals, Inc.
- 1550 East Gude Drive
- Rockville
- Maryland
- 20850
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SUPN | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | May 2012 |
| S49 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 2012 |
| 0LB2 | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | May 2012 |
Biography
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers O ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/08/22 00:29 |
| End of Day Share Price | 2019/08/21 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.